The COVID-19 remedy remdesivir dominated hospital drug spending in 2021, accounting for practically 10% of all pharmaceutical bills and outpacing the subsequent three medicine mixed, in response to the ASHP (American Society of Well being-System Pharmacists) Nationwide Developments in Prescription Drug Expenditures and Projections for 2022.
“Drug expenditures performed a major function within the rise in healthcare expenditures sparked by the COVID-19 pandemic,” stated Daniel J. Cobaugh, Pharm.D., FAACT, DABAT, vp of publishing at ASHP and editor-in-chief of AJHP. “Our annual report gives the vital context obligatory for hospital and health-system leaders, policymakers, and others to know the advanced components influencing drug expenditure patterns and put together for future development and spending.”
Complete drug spending within the U.S. grew 7.7% in 2021 to $576.9 billion. Hospitals accounted for $39.6 billion, with 8.4% development over 2020, and clinics accounted $105 billion in spending, a 7.7% enhance. Larger utilization and new medicine drove spending development, although drug costs decreased by as much as 1.4%. That state of affairs is more likely to change in 2022 if producers try and go alongside their elevated prices, the report stated.
“The drug spending whiplash that clinics and hospitals skilled within the first yr of the pandemic didn’t finish with 2021,” stated the report’s lead creator, Eric Tichy, Pharm.D., M.B.A., division chair, provide chain administration at Mayo Clinic, Rochester, Minnesota. “Uncertainty stays round how lengthy the federal authorities will proceed to pay for COVID therapies, and round inflation, which is transferring via most financial sectors.”
A moderating issue on drug spending was the elevated use of biosimilars, the generic variations of organic medicines. “Biosimilars actually took off this yr,” Tichy stated. “In oncology, we’re utilizing extra biosimilars than we’re the originator medicine. A few years in the past there was loads of consternation concerning the uptake of biosimilars being sluggish, however that has circled. Their use is more likely to proceed rising, and it’s saving the healthcare system some huge cash.”
New medicine additionally performed a job in spending development. Aducanumab, accredited in 2021 for Alzheimer’s illness, was anticipated to be a giant expense for clinics and hospitals because of its excessive value and a probably massive inhabitants. However spending on the drug was lower than $2 million, with the unexpectedly low utilization attributed to issues about knowledge supporting its use, excessive value, lack of readability about reimbursement, and complicated monitoring necessities.
In 2022, generics will possible have an effect on spending as a number of main branded medicine are anticipated to lose patent safety. This contains vasopressin, an antidiuretic in use for greater than a century that was nonetheless given patent safety beneath the Unapproved Medicine Initiative, making it the fifth-highest drug expense in hospitals.
New drug approvals are additionally anticipated in oncology, the highest spending class within the report. Tichy believes the Meals and Drug Administration will approve 5 new immune-checkpoint inhibitors, which deal with quite a lot of cancers and account for roughly a 3rd of oncology drug expenditures.
“After this yr we anticipate there to be 12 immune-checkpoint inhibitors available on the market,” Tichy stated. “All of them work equally, however we haven’t actually seen worth competitors between them. With extra immune-checkpoint inhibitors available on the market, we’re hopeful competitors might drive down costs.”
The report is printed on-line forward of print and can seem in print within the July 15 version of AJHP.
ASHP is the collective voice of pharmacists who function affected person care suppliers in hospitals, well being programs, ambulatory clinics, and different healthcare settings spanning the total spectrum of medicine use. The group’s greater than 60,000 members embody pharmacists, pupil pharmacists, and pharmacy technicians. For 80 years, ASHP has been on the forefront of efforts to enhance medicine use and improve affected person security. For extra details about the big selection of ASHP actions and the various methods during which pharmacists advance healthcare, go to ASHP’s web site, ashp.org, or its client web site, SafeMedication.com.
American Journal of Well being-System Pharmacy
Methodology of Analysis
Topic of Analysis
Nationwide Developments in Prescription Drug Expenditures and Projections for 2022
Article Publication Date
Dr. Tichy, Dr. Hoffman, and Dr. Rim are AJHP contributing editors. Dr. Suda is a member of the AJHP Editorial Advisory Board. The opposite authors have declared no potential conflicts of curiosity.
Disclaimer: AAAS and EurekAlert! will not be accountable for the accuracy of reports releases posted to EurekAlert! by contributing establishments or for using any info via the EurekAlert system.